I noticed a "Corporate Presentation" link on the Resverlogix homepage for the May slide deck. It appears that the Bloom Burton presentation links points to the same slides too. However, this slide deck is slightly different than the original posted Bloom Burton slide deck. Biggest difference is the 2018 Milestone/Upcoming Clinical Year estimates slide. Updated w/ added mention of the completion of the $30M financing, removal of mention of first US patients enrolled Q1, revised renal/Fabry Q3 start timeline. 

Also, the 2018 ERA-EDTA meeting kicks off next week. I just checked the program again and I see two apabetalone/bromodomain titles. Abstracts don't appear to be available, and I don't know what day/time they are happending. But here are the titles:

1) INHIBITION OF BET PROTEINS WITH APABETALONE REDUCES MEDIATORS OF VASCULAR CALCIFICATION IN VITRO AND IN CKD PATIENTS, presented by Ewelina Kulikowski

2) DESIGN FEATURES OF THE BETONMACE CHRONIC KIDNEY DISEASE SUB-STUDY; EFFECTS OF THE SELECTIVE BET-INHIBITOR APABETALONE ON KIDNEY FUNCTION AND MACE IN POST-ACS PATIENTS WITH ESTIMATED GLOMERULAR FILTRATION RATE BELOW 60 AND DIABETES, presented by Kam Kalantar-Zadeh

There will also be a satellite symposium on May 25 entitled "Epigenetics in CKD & CVD: A potential breakthrough therapy?" that will highlight the potential of BET inhibition in CKD and CVD. Agenda is below. As per past similar symposiums, presenations will be made available but there is several week lag period.

Agenda

Introduction, Vincent M Brandenburg, MD, University Hospital RWTH Aachen, Germany

Cardiovascular disease in diabetes and CKD & residual risk: The promise of epigenetics, Erik Stroes, MD, Academic Medical Centre, Amsterdam, The Netherlands

Epigenetics in CKD: Rationale for BET inhibition, an emerging therapeutic mechanism in renal disease and CVD, Louise Nordfors, MD, Karolinska Institute, Stockholm, Sweden

A clinical view on BET inhibition in CKD & CVD: Understanding recent data and future perspectives, Kamyar Kalantar-Zade, MD, UC Irvine School of Medicine, Irvine, Ca, USA

Discussion & summary, All faculty

BearDownAZ

P.S. It would be great if Resverlogix IR could start promoting, or at the very least listing on schedule of events, the conferences that that they are presenting at.